# Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)

> **NCT07733856** · — · AVAILABLE · sponsor: **Spruce Biosciences**

## Conditions studied

- Mucopolysaccharidosis Type IIIB
- MPS IIIB (Sanfilippo B Syndrome)

## Interventions

- **DRUG:** Tralesinidase alfa (TA)

## Key facts

- **NCT ID:** NCT07733856
- **Lead sponsor:** Spruce Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07733856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07733856, "Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07733856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*